Adjuvant Radiotherapy for High‑Risk Post‑Prostatectomy Patients (pT3a, Gleason 4 + 3)

Pathologic Risk Factors

A Gleason 4 + 3 = 7 (ISUP Grade Group 3) tumor with extraprostatic extension (pT3a) and negative surgical margins defines a high‑risk postoperative scenario that warrants adjuvant treatment, ideally initiated before postoperative PSA exceeds 0.2 ng/mL and with consideration of 4–6 months of short‑term androgen‑deprivation therapy (ADT) [1][2].
Non‑focal extraprostatic extension (i.e., extension beyond microscopic involvement) further increases the risk of recurrence and strengthens the indication for adjuvant therapy 3.

SWOG 8794 (randomized controlled trial) demonstrated that adjuvant radiotherapy improved 10‑year biochemical‑failure‑free survival (36 % vs 12 %; P = 0.001) and also yielded benefits in overall survival and metastasis‑free survival 3.
EORTC trial (randomized) showed a 5‑year biochemical progression‑free survival advantage for patients with positive margins or extraprostatic extension (78 % vs 49 %) when adjuvant radiotherapy was used 3.
German ARO 96‑02 trial (randomized) reported improved 5‑year biochemical progression‑free survival for pT3 disease with undetectable PSA (72 % vs 54 %; hazard ratio 0.53) after adjuvant radiotherapy 3.
High‑quality guideline bodies (NCCN 2014; EAU 2024) cite these trials as the strongest evidence supporting adjuvant radiotherapy for patients with the above adverse pathologic features [1][2]4.

Timing: Initiate adjuvant radiotherapy within 1 year after prostatectomy, once postoperative side effects have stabilized 2.
Dose: Deliver 64–70 Gy to the prostate‑bed in standard fractionation 2.
Technique: Use intensity‑modulated radiotherapy (IMRT) or volumetric‑modulated arc therapy (VMAT) with image‑guided radiotherapy (IGRT) for optimal target coverage and normal‑tissue sparing [2][4].
Target Volume: Treat the prostate bed; elective pelvic lymph‑node irradiation is optional and not required for node‑negative disease 2.

ADT alone has no therapeutic role in node‑negative postoperative patients [no citation – omitted].
Adding 4–6 months of short‑term ADT to adjuvant radiotherapy may be considered for Gleason 4 + 3 disease, based on extrapolation from primary‑radiation data [5][2].

If observation is chosen, monitor PSA every 3–6 months [3][2].
Salvage radiotherapy is most effective when PSA is < 0.5–1.0 ng/mL; treatment should be initiated after two consecutive rising PSA measurements [3][2].
Compared with observation, adjuvant radiotherapy reduces biochemical recurrence, local recurrence, and clinical progression more effectively 1; however, the impact on metastasis and overall survival remains less certain, with mixed results across trials 1.

The National Comprehensive Cancer Network (NCCN) (2014) and the European Association of Urology (EAU) (2024) give a strong (Level I) recommendation for adjuvant radiotherapy in patients with pT3a disease and Gleason 4 + 3 pathology [1][2]4.

The National Comprehensive Cancer Network recommends adjuvant ADT for patients with positive lymph nodes found during or after radical prostatectomy, as a category 1 option, which is the highest level of recommendation 6, 7
The Messing trial demonstrated that immediate ADT in node-positive patients improved overall survival at 11.9 years median follow-up, with a hazard ratio of 1.84 and 95% confidence interval of 1.01-3.35 8, 9

The National Comprehensive Cancer Network suggests that adjuvant radiotherapy, not ADT, is the appropriate adjuvant treatment for pT3 disease with adverse pathologic features, such as extracapsular extension, seminal vesicle invasion, or positive surgical margins 6, 7, 10
Adjuvant RT should be delivered within 1 year after surgery for patients with high-risk features, including extracapsular extension, seminal vesicle invasion, positive surgical margins, or short PSA doubling time [<9 months] [6, 7, 10]
The German trial by Wiegel et al found that adjuvant radiation improved 5-year biochemical progression-free survival in patients with pT3 disease and undetectable PSA after radical prostatectomy, with a hazard ratio of 0.53 6, 7, 10
SWOG 8794 demonstrated improved 10-year biochemical failure-free survival for high-risk patients with seminal vesicle invasion receiving adjuvant radiation, with a significant difference between the treatment and observation groups [P=.001] [6, 7, 10]

The National Comprehensive Cancer Network suggests that adding short-term ADT [4-6 months] to adjuvant radiation therapy may be considered for intermediate-risk features, such as Gleason 7, though this is primarily supported by data in the primary radiation setting, not post-prostatectomy 11, 9
ADT alone without radiation has no role in the adjuvant post-prostatectomy setting for node-negative disease, as it does not improve survival in these patients 8, 9